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The Iowa Newborn Screening Program (INSP) is administered by the Iowa Department of 
Health (IDPH) in collaboration with the University of Iowa State Hygienic Laboratory (SHL) to 
provide testing and the Stead Department of Pediatrics at the University of Iowa Stead Family 
Children’s Hospital to provide follow up services.   
 
 
Iowa Newborn Screening Dried Blood Spot Program Report  
Short Term and Long Term Follow Up Activities 
 
The following report describes the purpose, processes and activities of the short term and long 
term follow up program component of the Iowa Newborn Screening Program.  There is an 
appendix listing terms and definitions that readers may wish to refer to while reviewing this 
document.  Program staff members are willing to answer any questions the reader might have.  
Contact information is provided at the end of the report. 
 
Why Do Blood Spot Newborn Screening? 
 
Blood spot newborn screening can detect disorders that are life threatening or life changing 
before an untoward event occurs.  Babies can look and act perfectly healthy but still have one 
of these disorders.  Sometimes, it’s literally a matter of a few hours to a few days before 
tragedy can occur without newborn screening.  It is estimated that 12,000 babies are positively 
impacted by newborn screening efforts in the United States each year.  Newborn blood spot 
screening saves babies lives – it’s as simple as that.   
 
An Overview of the Laboratory and Clinical Process of Newborn Screening in 
Iowa 
 
Local Hospital - At 24-48 hours of age, a few drops of blood are taken from a baby’s heel to 
perform the newborn screening test.  These drops are placed on a card that contains 
information about the baby, the mother, and the blood sample.  This is called the dried blood 
spot card.   
 
Courier - The card is picked up at the local hospital by a courier service and is driven to our 
newborn screening laboratory in Ankeny.   Cards from throughout the state arrive in the 
laboratory around 9:00 pm each night (seven days a week). 
 
Newborn Screening Laboratory - Once the card arrives in the lab, quality checks are performed 
and the data from the card is entered into a database by data entry staff.  Laboratory staff start 
the testing process soon after the card arrives at the lab.  A laboratory staff member calls and 
emails the short term follow up staff with any abnormal endocrine or metabolic results so that 
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immediate (and sometimes life-saving) action can occur.  These results, along with testing 
results of other screened disorders, are entered into a database.   
 
Short Term Follow Up/Medical Consultant – Short term follow up staff are informed of 
abnormal testing results.  This is called a “presumptive positive” or “borderline” result.  
Presumptive positive means that the screening test for the disorder is abnormal and requires 
further action.  It does not mean that the baby has that disorder.  That is why the short term 
follow up component of the newborn screening program is crucial.   Follow up staff help local 
care providers through the process of determining if a screening result is real (i.e., a “true 
positive”) or a “false positive” (baby is not affected with a disorder/disease).  Follow up staff 
inform the local hospital (if baby is still an inpatient) or local provider (if baby has gone home) 
of the abnormal results.  Recommendations are provided to the primary care provider (PCP) 
verbally and then followed by a fax and/or email with the same information as per protocol.  
Education regarding the disorder that screened positive is also provided.  A medical consultant 
(a MD who specializes in one of the disorders that we screen for) will also review abnormal 
results and assist staff and local providers when necessary.   Sometimes it is recommended to 
repeat the newborn screen and/or to get additional specialized testing called confirmatory 
testing.  The follow up staff review the tests recommended with local providers (and sometimes 
local laboratories too) and keep in touch with the PCP to make sure that these tests are 
obtained.  Once the tests are obtained, follow up staff remain in communication with the local 
hospital or provider to obtain the results of further testing.  Once these results are in, follow up 
staff review the results with the medical consultant to see if further action is necessary.  
Sometimes no further action is necessary and the case is closed as a “false positive”.  If the 
specialized testing is reviewed and does not appear to be normal, then a referral is made to a 
specialist so the baby can be further evaluated.   
 
Long Term Follow Up – Referrals are made to specialized physicians and allied health care 
providers when a newborn screen is abnormal and/or a disorder is confirmed.  Sometimes, the 
long term follow up staff recommend additional testing or decide to start treatment.  For 
instance, if a baby is “presumptive positive” for PKU, a referral is made to a metabolic genetics 
center.  Confirmatory testing is performed if not yet completed or the results of the 
confirmatory tests are reviewed.  If it is determined that the baby has PKU, the parents are 
educated about the disorder and how to care for the child.  This includes information not only 
about the disorder, but extensive education on how to manage the special diet required to 
treat this condition is given by the metabolic dietitian.  The baby diagnosed with PKU will need 
to follow this special diet and will need to been seen by metabolic specialists for their lifetime.   
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Disorders Screened for in Iowa 
 
AMINO ACIDEMIAS AND UREA CYCLE DISORDERS 
• (ASA)  Argininosuccinic aciduria* 
• (CIT)  Citrullinemia, type 1 or ASA Synthetase Deficiency* 
• (HCY)  Homocystinuria (cystathionine beta synthetase)* 
• (MSUD)  Maple Syrup Urine Disease* 
• (PKU)  Classic Phenylketonuria* 
• (TYR-1)  Tyrosinemia, type I* 
• (ARG)  Argininemia** 
• (BIOPT-BS)  Defects of biopterin cofactor biosynthesis** 
• (CIT-II)  Citrullinemia, type II** 
• (BIOPT-REG)  Defects of biopterin cofactor regeneration** 
• (H-PHE)  Benign hyperphenylalaninemia** 
• (MET)  Hypermethioninemia** 
• (TYR II)  Tyrosinemia, type II** 
• (TYR III)  Tyrosinemia, type III** 
 
ORGANIC ACIDEMIAS 
• (GA-1)  Glutaric acidemia type I* 
• (HMG)  3-Hydroxy 3-methylglutaric aciduria * 
• (IVA)  Isovaleric acidemia* 
• (3-MCC)  3-Methylcrotonyl-CoA carboxylase* 
• (Cbl-A,B)  Methylmalonic acidemia (cobalamin disorders, vitamin B12 disorders)* 
• (βKT)  βeta-Ketothiolase* 
• (MUT)  Methylmalonic Acidemia (methylmalonyl-CoA mutase)* 
• (PROP)  Propionic acidemia* 
• (MCD)  Holocarboxylase synthase* 
• (2M3HBA)  2-Methyl-3-hydroxybutyric aciduria** 
• (2MBG)  2-Methylbutyrylglycinuria** 
• (3MGA)  3-Methylglutaconic aciduria** 
• (Cbl-C, D)  Methylmalonic acidemia with homocystinuria** 
•  (MAL)  Malonic acidemia** 
 
FATTY ACID OXIDATION DISORDERS 
• (CUD)  Carnitine uptake defect (Carnitine transport defect)* 
• (LCHAD)  Long-chain L-3 hydroxyacyl-CoA dehydrogenase* 
• (MCAD)  Medium chain acyl-CoA dehydrogenase* 
• (TFP)  Trifunctional protein deficiency* 
• (VLCAD)  Very long-chain acyl-CoA dehydrogenase* 
• (CACT)  Carnitine acylcarnitine translocase** 
• (CPT-Ia)  Carnitine palmitoyltransferase type I** 
• (CPT-II)  Carnitine palmitoyltransferase type II** 
• (GA2)  Glutaric acidemia type II** 
• (MCAT)  Medium-chain ketoacyl-CoA thiolase** 
• (M/SCHAD)  Medium/Short chain L-3-hydroxyacyl-CoA dehydrogenase** 
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ENDOCRINE 
• (CAH) Congenital adrenal hyperplasia * 
• (CH) Primary Congenital hypothyroidism * 
 
HEMOGLOBINOPATHIES 
• (Hb SS) S,S Disease (Sickle Cell Anemia)* 
• (Hb S/C) S,C Disease* 
• (HB S/βTh) S, βeta-thalassemia* 
• (Var Hb) Variant hemoglobinopathies ** 
 
OTHER 
• (BIOT) Biotinidase deficiency * 
•  (CF) Cystic Fibrosis * 
• (GALT) Classic Galactosemia * 
• (GALE) Galactoepimerase deficiency ** 
• (HEAR) Hearing loss*  
 
* Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC) 
Recommended Uniform Screening Panel - Core Panel 
 
** SACHDNC Recommended Uniform Screening Panel - Secondary Targets - Screening for the 
Core Panel of disorders may show information about secondary conditions (by-products of 
mandatory screening) 
 
Disorders on the SACHDNC recommended panel that we do not screen for: 
 (DE-RED) 2,4 Dienoyl-CoA reductase deficiency**;(GALK) Galactokinase deficiency**; 
(SCAD)  Short-chain acyl-CoA dehydrogenase**; (IBG)  Isobutyrylglycinuria**, Pompe, 
Mucopolysaccharidoses I (MPS 1) and Adrenoleukodystrophy (ALD).   
 
Screens Submitted (Calendar 2015) 
 
There were 41,276 newborn screening cards submitted to the newborn screening laboratory 
for testing (39,303 initial screens and 1,973 repeat screens).  This number includes more than 
one screen on some babies (repeat screens requested by follow up staff).   The number of 
births would be slightly less than the number of screens submitted. 
 
Borderline and Presumptive Positive Cases for CY 2015 
 
Disorder Borderline/ 
Indeterminate 
Presumptive Positive 
Biotinidase N/A 16 
Cystic Fibrosis 37 7 
Endocrine Disorders   
   Congenital Adrenal Hyperplasia 240 10 
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Congenital Hypothyroidism 456 17 
Galactosemia 3 3 
Hemoglobinopathies N/A 7 
Metabolic Disorders N/A 445 
Severe Combined Immunodeficiency N/A 6 
Confirmed Cases for Calendar 2015 
Confirmed cases are counted in the year that they were confirmed, not necessarily the year the 
baby was born.   
 
Primary Conditions 
 
Newborn screening is designed to find disorders that are designated as primary disorders on 
the Recommended Uniform Screening Panel (RUSP).  The confirmed cases listed below are only 
those disorders that have been designated as primary disorders on the RUSP.  Most metabolic 
disorders are identified through tandem mass spectrometry, but two metabolic disorders are 
enzyme based tests.  These are biotinidase deficiency and galactosemia.  These two disorders 
are listed separately in this table.  It should be pointed out that a very rare disorder, Long-Chain 
L-3 Hydroxyacyl-CoA Dehydrogenase (LCHAD), was detected in 2015.  This is the first time that 
this disorder has been identified in the INSP.  The incident rate is unknown because of the rarity 
of the disorder.   
 
Disorder Cases Confirmed 
Biotinidase Deficiency (metab) 2 
Cystic Fibrosis (CF) 6 
Endocrine Disorders  
  Congenital Adrenal Hyperplasia 0 
  Congenital Hypothyroidism 30 
Galactosemia (metab) 3 
Hemoglobinopathies  
  Hgb S/vs Hgb S Beta Thalassemia 2 
  Hgb SC  1 
Metabolic Disorders   
  2 MBG 1 
  Argininosuccinic Aciduria (ASA) 1 
  Cobalamin C 1 
  LCHAD 1 
  MCAD 5 
  PKU 6 
SCID 0 
TOTAL 59 
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Secondary Conditions or Incidental Findings 
 
Disorder Number Confirmed 
22q11.2 Deletion Syndrome 1 
Carriers of Various Metabolic Disorders 4 
Cystic Fibrosis Carriers 20 
Cystic Fibrosis Related Metabolic 
Syndrome (CRMS) 
5 
Duarte Galactosemia 2 
Hemoglobin EE  2 
Hemoglobin H 1 
Hemoglobinopathy Trait 477 
Hyperphenylalinemia  2 
Idiopathic T-Cell Lymphopenia 1 
Transient Tyrosinemia 1 
TOTAL 516 
 
False Negative Case  
 
When a baby is diagnosed with a disorder that we screen for, but the screening was reported as 
negative (normal), we refer to it as a “false negative”.   The program has to rely on individuals 
to report false negatives to the program because there is no other way to ascertain them.  
Often, we hear of these cases from the baby’s PCP or through specialists.  Although we strive to 
not have any false negatives, it does occur, especially in cystic fibrosis.  The medical community 
knew before we started screening for cystic fibrosis that there would be a 10% false negative 
rate.  The incidence of a false negative in cystic fibrosis increases when the baby has meconium 
ileus.  This points out a very important fact; newborn screening is a screening test, not a 
diagnostic test.   
 
We had 1 false negative case in 2015 for cystic fibrosis in a baby with meconium ileus. 
 
Missed Screens – 1  
 
One birthing facility failed to get a baby screened prior to discharge.  The missed screen was 
discovered by the baby’s PCP when she went to review NBS results with the parents at the 2 
week routine check up.  Baby was finally screened at about 4 weeks of life.  The birthing facility 
was contacted and technical assistance and education was provided. 
 
Lost to Follow Up/Against Medical Advice - 18 
 
There were 18 babies who were categorized as lost to follow up or did not follow through with 
recommendations given to them by medical professionals and/or the newborn screening 
program.  Thirteen babies were lost to follow up.  Lost to follow up is when a baby cannot be 
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found by the baby’s PCP or by the program (such as when a phone is disconnected and/or 
certified mail is returned) or when parents are contacted but do not bring the baby in for a 
recommended repeat screen or confirmatory testing despite multiple attempts to get them to 
do so.  Seven of the 13 babies lost to follow up had an initial poor quality screen.  See “Poor 
Quality Screens” later in this section.  There were 5 babies that were “AMA” – against medical 
advice.  These are situations where the PCP or program personnel have had an informed, 
educational conversation with the family about why they are recommending further testing and 
the parents still refuse after being appropriately counseled about what might happen if they do 
not do further testing. 
 
Poor Quality Screens - 408 – 1.0% 
 
There are various reasons that newborn screening samples are considered to be “poor quality”.  
The sample could be contaminated, there isn’t enough blood within the circles on the card, the 
blood spot is layered or clotted, the blood spot card has expired, etc.  Screens are rejected 
when lab staff determines that the accuracy of the test results would be compromised for any 
of the reasons listed above.   
 
Currently, the state percentage for poor quality samples is 1.0%.  Compared to many other 
state programs, 1.0% is an acceptable number.  However, the INSP would like the state average 
to be < 1.0%.  The program provides technical assistance/education to reduce the percentage 
of poor quality screens in our state.  It is imperative that a good quality screen be collected the 
first time.  When it isn’t, the baby’s health could be impacted.  Poor quality screens also 
increase the number of babies who never get a valid screen (see “lost to follow up” above).  
Finally, poor quality screens negatively impact timeliness in newborn screening.   
 
Refusals -23 – Started tracking July 1, 2015 
 
On July 1, 2015, the Iowa Department of Public Health instituted a new rule in the Iowa Code 
that reads as follows:  that ITEM 6. Amend paragraph 4.3(2)“b” as follows: 
 b.  Refusal of screening. Should a parent or guardian refuse the screening, said refusal 
shall be documented in the infant’s medical record, and the parent or guardian shall sign the 
refusal of screening form. The birthing facility or attending health care provider shall submit the 
signed refusal of screening form to the central laboratory within six days of the refusal. The 
birthing facility or attending health care provider may submit refusal forms via the courier 
service established for the transportation of newborn screening specimen collection forms.  
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It was decided that the refusal forms would be sent to NBS follow up staff for review because of 
other tracking activities done by the follow up program.  There were 23 refusals from July 1, 
2015 – December 31, 2015.  The reasons listed on the form for refusals include:  “don’t see the 
necessity in doing the screen”,” religious reasons”, “cost” (for self pay patients), “my other kids 
are fine”, and “too many false positives”.  We continue to do educational outreach to parents 
and providers so that they understand the importance of screening and the implications of not 
screening.   
 
See “Quality Improvement” for information on a project with refusals. 
 
Genetic Counseling 
 
Genetic counseling is offered to all patients who have abnormal test results through the 
newborn screening process.  The counseling is completed either face to face or over the phone.  
We hope to offer more genetic counseling through telehealth (like Skype) in the future.   
 
Quality Improvement Activities (Fiscal Year 2016) 
 
QI Officer 
 
A new position for a Quality Improvement Officer was filled in 2015 by Ashley Comer, one of 
the NBS lab technologists.  Although housed in the NBS lab, Ashley works with NBS personnel at 
the IDPH, SHL Coralville and follow up staff at UIHC to improve the quality of our program.  One 
of the position’s primary duties Ashley has is to interface and provide technical assistance to 
birthing centers and midwives across the state of Iowa. 
 
Timeliness in Newborn Screening 
 
The program’s timeliness activities started in late 2014 when our NBS program was selected to 
participate in a non-funded Collaborative Improvement and Innovation Network (COIIN) to 
Improve Timeliness in Newborn Screening sponsored by the Health Resource Services 
Administration (HRSA)/Association of Public Health Laboratories (APHL).  Participants in the 
COIIN included  Stan Berberich from the SHL NBS lab; Kristen Ernsperger, nurse from Des 
Moines Mercy Medical Center; Carol Johnson, NBS follow up; Laura Malone, Iowa Hospital 
Association; and Kim Piper from IDPH.  We determined our timeliness goal would be that 95% 
of NBS samples would arrive in the NBS laboratory =< 60 hours after birth.  Throughout 2015, 
we developed and implemented a timeliness report that is sent to all birthing facilities and 
midwives.  Program staff has also participated in several hospital visits and have spoken at 
various meetings to provide general NBS education as well as education on timeliness in NBS.  
In 2015, the Iowa Newborn Screening Program applied for and was granted funding from 
APHL/NewSTEPs 360 to continue work on timeliness in newborn screening.   
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Baby Matching  
 
Baby matching is the process of “matching” a newborn screening result or an official NBS 
refusal form with birth certificates to make sure that all babies born in the state have been 
screened.  Matching is completed by the IDPH and then a lists of babies who do not appear to 
have a NBS are sent to follow up staff to reconcile.  If NBS results cannot be found, the birthing 
hospital is contacted to see if a screen was collected.  If not, the baby’s PCP is notified and 
asked to obtain the screen as soon as possible.  Often we find that a baby has been screened in 
a bordering state.  On occasion we find that a baby did not get screened.  This process reduces 
the number of babies who do not get screened. 
 
Refusals 
 
The follow up staff member who does baby matching worked with our genetic counselor on a 
project to follow up on NBS refusals.  The counselor would call the parents to talk with them 
about the NBS refusal.  She would answer any questions that they had.  We wondered if this 
one on one interaction where the parents could be fully educated about NBS would make 
parents reconsider and get their baby screened.  Several admitted that they hadn’t gotten any 
NBS education (whether this was the first baby or the fifth baby).  Some said that if they would 
have received the education on NBS that was provided by the counselor, they probably would 
have made a different choice.  However, only one parent changed their mind and got their baby 
screened.  We stopped having the counselor make these calls as the benefit was not greater 
than the time and effort being put into the project. 
 
Severe Combined Immunodeficiency 
 
1) Newborn screening personnel from the laboratory and follow up continue to closely 
monitor results from SCID NBS.  Staff meets quarterly to go over laboratory data as well 
as clinical data to make sure things continue to go well for the newest disorder added to 
our NBS panel.   
 
2) Normative Values for Flow Cytometry – The University of Iowa is the only Flow 
Cytometry Laboratory in the state.  When a baby is presumptive positive for SCID, the 
next step is to obtain a whole blood sample and send it to a flow cytometry laboratory 
for confirmatory testing.  Unfortunately, there are no normative values established in 
flow cytometry for preterm or full term infants in the world.  Therefore, the SCID 
medical consultant, Dr. Mary Beth Fasano, and our Flow Cytometry SCID medical 
consultant, Dr. Sergei Syrbu, are conducting research with colleagues in the University 
of Iowa Hospitals and Clinics Labor and Delivery Suite and the University of Iowa Blood 
Bank to determine what a normative value is on newborns at various gestational ages.  
Parents are consented to be a part of this study.  Emily Phillips is the research 
coordinator for the project. 
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Case Closure-Metabolic 
 
The metabolic short and long term follow up staff, as well as laboratory staff. meet once per 
month to go over all borderline/presumptive positive metabolic cases that have been identified 
during the month.  During this meeting, cases are reviewed and discussed.  We find that some 
cases can be closed and that some cases are still pending.  Education on metabolic disorders is 
also provided from the clinical staff.  This process allows us to ensure that cases are closed in a 
timely manner and that NBS cases are not lost during the follow up process. 
 
Protocols and Educational Materials  
 
Protocols and educational materials for each disorder are reviewed on a yearly basis, but can 
also be reviewed and altered on an as needed basis.  Often, case experience brings an issue to 
light and changes to the protocols need to be made.  Because this is a large undertaking (over 
120 protocols and related educational material), follow up staff work on protocols all year long.   
 
Database  
 
The INSP is in the middle of switching over to an integrated database for the three newborn 
screening programs called the Iowa Newborn Screening Information System (INSIS).  We 
continue to work on identifying needs as OZ Systems continues to build the blood spot 
newborn screening module.  Weekly meetings have been occurring throughout this fiscal year.  
We have done one round of User Acceptance Training.  We anticipate going live with this new 
database in December 2016.   
 
Projects 
 
NewSTEPs Repository 
 
Confirmed cases are entered into this national repository by our follow up staff.  At this time, 
NewSTEPs is still working on case definitions for hemoglobinopathies and SCID, so any 
confirmed cases of these disorders are not currently in this repository. 
 
Region 4 Repository 
 
Any confirmed metabolic or SCID cases are entered into this international repository by our 
follow up staff.  This repository is also used as a tool for all presumptive positive metabolic 
cases.  It gives a case score and lists all the possible metabolic conditions that could be 
associated with the metabolic analyte results.   
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Multidisciplinary Sickle Cell Comprehensive Clinic 
 
Dr. Anjali Sharathkumar, along with Dr. Vasu Kailasnath, social worker Abby Yoder and 
psychologist Amanda Grafft from University of Iowa Children’s Hospital have been working to 
establish a comprehensive sickle cell clinic for patients with hemoglobinopathies in the state of 
Iowa.  The clinic was started mid FY 16 and takes place at the Iowa River Landing Clinic in 
Coralville, Iowa.  The response has been positive so far.  This multidisciplinary clinic is held once 
per month and includes MD medical consultation, genetic counseling (patient and group 
counseling and education), social work, and psychological services.    
 
Education Presentations and Technical Assistance 
 
The INSP provides education and technical assistance to NBS stakeholders throughout the state 
in a variety of ways.  These include on site presentations, postings on the IDPH NBS list serve, 
webinars, mailings, phone calls, etc.  We believe that education is the core activity for all other 
quality improvement initiatives.  For a more in depth look at INSP educational activities 
provided by follow up staff, please see the educational activities list later in this report. 
 
New Dried Blood Spot Card 
 
Program staff has been working on revising the dried blood spot card.   It is our hope that the 
changes being made will enhance the quality of the data collected on the card so that test 
interpretation will be more specific and identifying the baby’s PCP will be easier.  Changes 
planned include:  1) changing verbiage from “mother” to “guardian” in the next of kin field; 
adding a check box for meconium ileus (if present, baby likely has CF and the lab will go directly 
to DNA testing); revising the feeding method section, and changing/adding the physician 
information field to include the ability to list both the attending physician (person who ordered 
the NBS) and identifying the PCP who will care for the baby after discharge.  Often, the name of 
the ordering physician is listed on the blood spot card, but the follow up staff need to interact 
with the baby’s PCP for any abnormal screening results.  We anticipate the new card will begin 
to be used approximately February 2017.  
 
New Brochure 
 
The Iowa Department of Public Health developed a new newborn screening brochure that 
encompasses the three newborn screening programs:  blood spot screening, critical congenital 
heart disease screening, and hearing screening.  The feedback has been positive from staff in 
birthing facilities; they like having all the newborn screening information in one brochure. 
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Facility Data Report 
 
The INSP is working on revising the facility data report.  This is a quality report sent to all 
birthing facilities.  It includes information such as their poor quality rate, how many early 
collections there were (< 24 hours), and other quality indicators.  We are working to include 
information on how well the card was filled out upon arrival in the NBS lab and also sharing 
information in a generic way about the confirmed cases that have been identified through NBS.   
 
Federal Express vs Certified Letter  
 
Sometimes, local PCP’s and the INSP are unable to reach a family when there are outstanding 
recommendations because of abnormal newborn screening test results.  When this happens, a 
certified letter is sent to the mother explaining that she needs to contact her baby’s PCP and 
make arrangements to come in for further testing.  Follow up staff had received feedback that 
families tend to ignore certified letters as certified letters have the connotation of containing 
“bad news”, usually financial or legal issues.  Follow up staff tried an experiment to see if using 
Federal Express to send these letters resulted in better follow through from families in general, 
and if that follow through was more timely than what is observed with a certified letter.  
Overall, we only had one case where sending the letter via Federal Express made things happen 
in a more timely fashion. Therefore, we are still using certified mail.  
 
Other Projects and Relevant Information 
 
Inborn Errors of Metabolism Collaborative Research Project – this is a natural history, 
consented patient registry for those patients with metabolic conditions.  Emily Phillips is the 
research coordinator. 
 
Clinical Trials/Patient Registries – the metabolic and lysosomal storage clinical teams participate 
in various clinical trials being conducted at the University of Iowa Children’s Hospital for these 
disorders. 
 
 
 
 
Educational Activities 
 
Name Date(s) Presentation Title Type Name of 
Meeting 
Location 
of Meeting 
Attendee 
Only 
John Bernat 2/29-3/4/16   WORLD 
2016 
Lysosomal 
Meeting  
San Diego, 
CA 
X  
Natalie Dennler 11/4/15  Vendor University 
of Iowa 
Health Fair 
Iowa City, 
IA 
 
 2/8/16   Pregnancy 
Centering 
Group 
Iowa River 
Landing 
Clinic, 
Coralville, 
IA 
 
 2/29-3/3/16   Newborn 
Screening 
and Genetic 
Testing 
Symposium 
St. Louis, 
MO 
X 
 4/25/16   Pregnancy 
Centering 
Group 
Iowa River 
Landing 
Clinic, 
Coralville, 
IA 
 
Fasano, Mary 
Beth 
11/5-9/15   American 
College of 
Allergy, Asthma, 
and 
Immunology 
Annual Meeting 
San 
Antonio, 
TX 
X 
15 
 
 1/22/16 “When Eczema Isn’t 
Just Eczema:   How Not 
to Miss Immune 
Disorders” (included 
SCID) 
Presenter Clinical 
Symposia – 
Advances in 
Dermatology 
Naples, FL  
 3/4-7/16   American 
College of 
Allergy, 
Asthma, and 
Immunology 
Annual 
Meeting 
Los 
Angeles, 
CA 
 
 5/19/16   North Dakota 
Newborn 
Screening 
Advisory 
Committee 
Bismarck, 
ND 
X 
 5/20/16 “Newborn Screening for 
SCID – What Iowa Has 
Learned So Far” 
Presenter North Dakota 
Newborn 
Screening 
SCID 
Conference 
Bismarck, 
ND 
 
Hatland, 
Tammy 
10/7/15  Vendor Neonatal 
Update 
Conference 
Marriott, 
Coralville, 
IA 
 
 11/4/15  Vendor University 
of Iowa 
Health Fair 
Iowa City, 
IA 
 
 2/29-3/3/16   Newborn 
Screening 
and Genetic 
Testing 
Symposium 
St. Louis, 
MO 
X 
16 
 
Hobert-
Mellecker, 
Melody 
10/6/15  Vendor Children 
and 
Women’s 
Services Fall 
Conference, 
sponsored 
by the 
University 
of Iowa 
Holiday 
Inn, 
Coralville, 
IA 
 
 11/6/15 “Together-Saving 
Babies One Foot at a 
Time” 
Presenter 
with 
Ramirez 
Northwest 
Iowa 
Regional 
Best 
Practices in 
Newborn 
Screening 
Conference 
Sheldon, IA  
 11/30/15 “Together – Saving 
Babies Lives One Foot 
at a Time” 
Presenter  Great Rivers 
Medical 
Center 
Burlington, 
IA 
 
 12/17/15  Presenter Pregnancy 
Centering 
Group 
Iowa River 
Landing 
Clinic, 
Coralville, 
IA 
 
 2/29-3/3/16   Newborn 
Screening 
and Genetic 
Testing 
Symposium 
St. Louis, 
MO 
X 
17 
 
 5/19/16   North 
Dakota 
Newborn 
Screening 
Advisory 
Committee 
Bismarck, 
ND 
X 
 5/20/16   North 
Dakota 
Newborn 
Screening 
SCID 
Conference 
Bismarck, 
ND 
X 
 5/22-29/16  Trainee APHL 
Tandem 
Mass 
Spectrometry 
Workshop 
Silver 
Spring, MD 
X 
Holida, Myrl 2/29-3/4/16   WORLD 
2016 
Lysosomal 
Meeting  
San Diego, 
CA 
X  
 3/25/2016 “Lysosomal Storage 
Diseases” 
Presenter Grand 
Rounds, 
Dept. of 
Pediatrics 
UIHC, Iowa 
City, IA 
 
Johnson, Carol 
(National) 
10/7/2015 “Barriers to Timeliness 
in Newborn Screening” 
Presenter Quality 
Improvement 
Special Interest 
Group, North 
American Cystic 
Fibrosis 
Foundation 
Symposium 
Phoenix, 
AZ 
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 11/2/2015 “Barriers to Timeliness 
in Newborn Screening” 
Presenter Advisory 
Committee 
to HHS 
Secretary on 
Newborn 
Screening 
and Genetic 
Testing, 
Subcommittee 
on Timeliness 
in Newborn 
Screening  
Webinar   
 2/29-3/3/16 “Collaborative 
Improvement and 
Innovation Network 
for Timeliness in 
Newborn Screening – 
the Iowa Experience to 
Date” 
Poster Newborn 
Screening 
and Genetic 
Testing 
Symposium 
St. Louis, 
MO 
 
 2/29/2016 Roundtable Discussion 
“Short Term Follow Up 
Processes in Newborn 
Screening” 
Facilitator Newborn 
Screening 
and Genetic 
Testing 
Symposium 
St. Louis, 
MO 
 
 3/1/2016 Short Term Follow Up 
Mixer – Facility 
Reports 
Facilitator Newborn 
Screening 
and Genetic 
Testing 
Symposium 
St. Louis, 
MO 
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 6/21-22/16 “Barriers to Timeliness 
in Newborn Screening” 
Presenter Cystic Fibrosis 
Newborn 
Screening 
Quality 
Improvement 
and Timeliness 
Meeting, 
APHL/NACFF 
Denver, 
CO 
 
 6/23/2016 “Improving Efficiency 
in Newborn Screening 
Collection and Test 
Results” 
Presenter Robert 
Wood 
Johnson 
Foundation 
Webinar  
Regional 5/1/15 “Timeliness in 
Newborn Screening 
and the COIIN 
Initiative” 
Presenter 
with Kim 
Piper 
Heartland 
Regional 
Genetics 
Collaborative 
Annual 
Meeting 
Kansas 
City, MO 
 
 2/24/16 “Heartland COIIN for 
Timeliness in Newborn 
Screening” 
Presenter 
with Kim 
Piper and 
Ashley 
Comer 
Heartland 
Regional 
Collaborative 
Newborn 
Screening 
Subcommittee 
Webinar  
 5/5-6/16 Heartland Timeliness 
Workshop 
Presenter/
Facilitator 
with 
Berberich, 
Comer, 
Piper 
Kansas City 
Airport 
Marriott 
Kansas 
City, MO 
 
 5/19/16   North Dakota 
Newborn 
Screening 
Advisory 
Committee 
Bismarck, 
ND 
X 
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 5/20/16 “Newborn Screening 
Follow Up – What’s it 
All About?” 
Presenter North 
Dakota 
Newborn 
Screening 
SCID 
Conference 
Bismarck, 
ND 
 
State/Local 7/15/15 
7/20/15 
“Together – Saving 
Babies Lives One Foot 
at a Time” 
Presenter St. Luke’s 
Unity Point 
Medical 
Center 
Cedar 
Rapids, IA 
 
 9/22/2015 “COIIN Timeliness in 
Newborn Screening – 
The Iowa COIIN 
Initiative” 
Presenter 
with Stan 
Berberich 
St. Luke’s 
Unity Point 
Medical 
Center 
COIIN Team 
Cedar 
Rapids, IA 
 
 11/10/15  Vendor Iowa 
Healthcare 
Collaborative 
Meeting 
Altoona, IA  
 11/30/15 “Together – Saving 
Babies Lives One Foot 
at a Time” 
Presenter 
with 
Melody 
Hobert-
Mellecker 
Great Rivers 
Medical 
Center 
Burlington, 
IA 
 
 1/13/16 “Timeliness in 
Newborn Screening for 
Birthing Centers – 
Iowa’s COIIN Project” 
Presenter 
with 
Berberich, 
Comer, 
Piper 
Birthing 
Facilities 
and 
Midwives 
throughout 
Iowa 
Webinar  
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 4/6/16  Vendor Iowa 
Statewide 
Perinatal 
Conference 
Des 
Moines, IA 
 
 4/12/16 “COIIN Timeliness in 
Newborn Screening “ 
Presenter 
with 
Berberich, 
Comer, 
MPH 
student 
Mercy 
Medical 
Center 
Dubuque, 
IA 
 
 4/12/16 “COIIN Timeliness in 
Newborn Screening “ 
Presenter 
with 
Berberich, 
Comer, 
MPH 
student 
Finley 
Medical 
Center 
Dubuque, 
IA 
 
 4/15/16 “COIIN Timeliness in 
Newborn Screening “ 
Presenter 
with 
Berberich, 
Comer, 
MPH 
student 
Mercy 
Hospital 
Iowa City, 
IA 
 
 4/21/16 “The Iowa Newborn 
Screening Program – 
Saving Babies One 
Foot at a Time” 
Presenter Iowa 
Leadership 
Education in 
Neurodevelop-
mental and 
Related 
Disabilities 
Iowa City, 
IA 
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Marcy, Jennifer 7/1/2015-
6/30/2016 
Genetic counseling for 
patients/families being 
seen for CF sweat 
testing 
Counselor Cystic 
Fibrosis 
Center 
Pediatric 
Specialty 
Clinic, 
University 
of Iowa 
Children’s 
Hospital 
Iowa City, IA 
 7/1/2015-
6/30/2016 
Genetic counseling for 
patients/families being 
seen for positive 
confirmatory testing 
for SCID 
Counselor Pediatric 
Immunology 
Clinic 
Pediatric 
Specialty 
Clinic, 
University 
of Iowa 
Children’s 
Hospital 
Iowa City, IA 
 7/1/2015-
6/30/2016 
Genetic counseling for 
patients with a 
confirmed disorder 
screened for by the 
INSP 
Counselor Telephone Office Iowa City, IA 
 February 
2016 
Genetic counseling and 
disorder education for 
patients with 
hemoglobinopathies; 
single counseling and 
educational sessions 
along with group 
counseling and 
educational sessions 
Presenter/
counselor 
Multidisciplinary 
Sickle Cell 
Clinic 
Iowa River 
Landing 
clinic, 
University 
of Iowa, 
Coralville, 
IA 
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 2/29-3/3/16   Newborn 
Screening 
and Genetic 
Testing 
Symposium 
St. Louis, 
MO 
X 
Miller, Judy July 2015 “The Use of Kuvan in 
the Treatment of PKU” 
Organizer, 
presenter 
PKU Low 
Protein 
Cooking 
Event 
Hotel 
Kirkwood, 
Cedar 
Rapids, IA 
 
 8/4-5/15   Heartland 
Telemedicine 
Training 
Little Rock, 
AK 
X 
 4/6/2016  Organizer Low Protein 
Grocery 
Store Event 
Hy-Vee 
Grocery 
Store, East 
Des 
Moines, IA 
X 
 4/27-30/16   Genetics 
Metabolic 
Dietitians 
International 
Phoenix, 
AZ 
X 
 5/14/2016  Organizer PKU Family 
Event 
(sponsored 
by BioMarin) 
Blank Park 
Zoo, Des 
Moines, IA 
X 
 6/21/2016  Organizer Low Protein 
Grocery 
Store Event 
Hy-Vee 
Grocery 
Store, 
Cedar 
Rapids, IA 
X 
Norris, Andrew  Nothing to report     
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Phillips, Emily 7/20/15 “Together – Saving 
Babies Lives One Foot 
at a Time” 
 St. Luke’s 
Unity Point 
Medical 
Center 
Cedar 
Rapids, IA 
X 
 8/2/15  Vendor – 
Importance 
of NBS 
Corridor 
Parent Expo 
Hotel 
Kirkwood, 
Cedar 
Rapids, IA 
 
 8/19/15 
11/18/15 
6/1/16 
“NICU Nursing 
Orientation for 
Newborn Screening” 
Presenter UIHC NICU Iowa City, 
IA 
 
 8/19/15 
8/31/15 
10/23/15 
11/19/15 
1/13/16 
2/10/16 
3/9/16 
4/7/16 
5/4/16 
“The Importance of 
Newborn Screening 
and Timeliness and 
How to Collect a 
Screen” 
Presenter Newborn 
Screening 
Education for  
Residents 
Prior to 
NICU/Nursery 
Rotations  
Iowa City, 
IA 
 
 8/22/15  Vendor Iowa State 
Fair 
Des 
Moines, IA 
 
 9/9/15 
11/9/15 
 Presenter Pregnancy 
Centering 
Group 
Iowa River 
Landing 
Clinic, 
Coralville, 
IA 
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 9/21/15 
11/2/15 
1/11/16 
2/22/16 
4/4/16 
5/16/16 
“The Importance of 
Newborn Screening and 
Timeliness and How to 
Collect a Screen” 
Presenter Newborn 
Screening 
Education for  
Medical 
Students Prior 
to 
NICU/Nursery 
Rotations  
Iowa City, 
IA 
 
 10/26/15  Vendor Association 
of Women’s 
Health, 
Obstetrics 
and 
Neonatal 
Nurse State 
Conference 
Des 
Moines, IA 
 
 11/4/15  Vendor University of 
Iowa Health 
Fair 
Iowa City, 
IA 
 
 4/5/16  Vendor Iowa 
Statewide 
Perinatal 
Conference 
Des 
Moines, IA 
 
 5/19/16   North 
Dakota 
Newborn 
Screening 
Advisory 
Committee 
Bismarck, 
ND 
X 
 5/20/16   North Dakota 
Newborn 
Screening 
SCID 
Conference 
Bismarck, 
ND 
X 
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Serrano Russi, 
Alvaro 
10/8/15 “Metabolic Disease 
and Emergencies” 
Presenter Department 
of Pediatrics 
Residency 
Program 
UIHC 
Iowa City, 
IA 
 
 12/17/15 “Inborn Errors of 
Metabolism 
Associated with Critical 
Illness” 
Presenter Pediatric 
Intensive 
Care-Fellow 
Core 
Curriculum 
UIHC 
Iowa City, 
IA 
 
 1/21/15; 
3/25/15; 
4/15/15; 
1/26/16 
“Newborn Screening 
Overview” 
Presenter Educator 
Early Clinical 
Experience 
for First Year 
Medical 
Students 
UIHC 
Iowa City, 
IA 
 
 2/29-3/3/16 “Glutaric Acidemia 
Type II and LCHAD 
Deficiency Cases 
Identified by Newborn 
Screening Short Term 
Outcome” 
Poster Newborn 
Screening 
and Genetic 
Testing 
Symposium 
St. Louis, 
MO 
X 
  “Two Year Clinical Follow 
Up of a Patient with 
Methylbutyrylglycinuruia 
Identified by Newborn 
Screening” 
Poster Newborn 
Screening 
and Genetic 
Testing 
Symposium 
St. Louis, 
MO 
X 
 4/3-6/16 “Incidental 
Medulloblastoma in 
Adolescent with 
Known Glutaric 
Acidemia Type 1” 
Poster Society of 
Inborn 
Errors of 
Metabolism 
Ponte 
Vedra 
Beach, FL 
X 
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Sharathkumar, 
Anjali 
October 
2015 
  Heartland 
Sickle Cell 
Network 
Annual 
Meeting 
St. Louis, 
MO 
X 
 October 
2015 
  Meeting 
with the 
Washington 
University 
Sickle Cell 
Team and 
Clinic 
St. Louis, 
MO 
X 
Starner, 
Timothy 
10/8-10/15   North 
American 
Cystic 
Fibrosis 
Foundation 
Meeting 
Phoenix, 
AZ 
X 
 6/21-22/16   Cystic 
Fibrosis 
Newborn 
Screening 
Quality 
Improvement 
and 
Timeliness 
Meeting 
Denver, 
CO 
X 
Stimson, Cheryl July 2015  Organizer PKU Low 
Protein 
Cooking 
Event 
Hotel 
Kirkwood, 
Cedar 
Rapids, IA 
X 
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 4/6/2016  Organizer Low Protein 
Grocery 
Store Event 
Hy-Vee 
Grocery 
Store, East 
Des 
Moines, IA 
X 
 4/27-30/16   Genetics 
Metabolic 
Dietitians 
International 
Phoenix, 
AZ 
X 
 5/14/2016  Organizer PKU Family 
Event 
(sponsored 
by BioMarin) 
Blank Park 
Zoo, Des 
Moines, IA 
X 
 6/21/2016  Organizer Low Protein 
Grocery 
Store Event 
Hy-Vee 
Grocery 
Store, 
Cedar 
Rapids, IA 
X 
 6/30/2016  Co-Author, 
Chapter  
Simplified 
Diet Manual 
on PKU 
  
 
 
Committees 
 
Name Committee Name Role 
Bernat, John Management of the Iowa Newborn 
Screening Panel Subcommittee 
Member 
 Center for Congenital and Inherited 
Disorders Advisory Committee (CIDAC) 
Ex-Officio 
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Hatland, Tammy Newborn Screening Information System  
Subcommittee 
Member 
Hobert-Mellecker, 
Melody 
North Dakota Newborn Screening 
Advisory Committee 
Member 
 Management of the Iowa Newborn 
Screening Panel Subcommittee 
Member 
 Heartland Genetics Collaborative 
Newborn Screening Workgroup 
Member 
Holida, Myrl Center for Congenital and Inherited 
Disorders Advisory Committee 
Ex-Officio 
Johnson, Carol APHL/New STEPs Short Term Follow Up 
Workgroup 
Co-Chair 
 NewSTEPs/Cystic Fibrosis Foundation 
Special Interest Group on Improving 
NBS and Timeliness for Cystic Fibrosis 
Member 
 APHL NBS Steering Committee Member 
 Heartland Genetics Collaborative 
Newborn Screening Workgroup 
Member 
 North Dakota Newborn Screening 
Advisory Committee 
Member 
 Center for Congenital and Inherited 
Disorders Advisory Committee 
Ex-Officio 
 Management of the Iowa Newborn 
Screening Panel Subcommittee 
Member 
 Newborn Screening Information System  
Subcommittee 
Chair 
 CIDAC Informed Consent Subcommittee Member 
 CIDAC Use and Retention of Dried 
Blood Spot Subcommittee 
Member 
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 Newborn Screening COIIN for 
Timeliness Team 
Member 
 Iowa NBS Executive Committee Member 
Marcy, Jennifer Management of the Iowa Newborn 
Screening Panel Subcommittee 
Chair 
Phillips, Emily CIDAC Informed Consent Subcommittee Member 
 Management of the Iowa Newborn 
Screening Panel Subcommittee 
Member 
Serrano-Russi, 
Alvaro 
Center for Congenital and Inherited 
Disorders Advisory Committee 
Ex-Officio 
 Management of the Iowa Newborn 
Screening Panel Subcommittee 
Member 
Sheffield, Val Center for Congenital and Inherited 
Disorders Advisory Committee 
Member 
 Iowa NBS Executive Committee Member 
Starner, Timothy  NewSTEPs/Cystic Fibrosis Foundation 
Special Interest Group on Improving 
NBS and Timeliness for Cystic Fibrosis 
Member 
 
 
 
 
 
 
 
 
 
Program Personnel – Follow Up Services (Fiscal Year) 
 
 
Name Title Disorder Location 
Bernat, John MD Medical 
Consultant 
Lysosomal Storage 
Disorders 
Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals and 
Clinics 
Iowa City, IA 
DeBoer, Pamela  Metabolic Disorders Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals and 
Clinics 
Iowa City, IA 
Dennler, Natalie Case Manager, Short 
Term Follow Up 
Iowa Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals and 
Clinics 
Iowa City, IA 
Endocrinologist On 
Call – Vanessa Curtis, 
Katie Larsen Ode, 
Andrew Norris, Liuska 
Pesce, Michael 
Tansey, Eva Tsalikian 
MD On Call Endocrine Disorders 
(Congenital Adrenal 
Hyperplasia; Congenital 
Hypothyroidism) 
Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals and 
Clinics 
Iowa City, IA 
Fasano, Mary Beth MD Medical 
Consultant 
SCID Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals and 
Clinics 
Iowa City, IA 
Ferguson, Polly MD Medical 
Consultant (back up 
to Dr. Fasano) 
SCID  Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals and 
Clinics 
Iowa City, IA 
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Genetics On Call – 
John Bernat, Alvaro 
Serrano-Russi, Val 
Sheffield, Pamela 
Trapane 
MD On Call Primarily metabolic 
disorders, but the 
geneticist on call 
triages all incoming 
NBS calls after hours, 
weekends, and 
holidays 
Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
Hatland, Tammy Case Manager, Short 
Term Follow Up 
Iowa Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
Hobert-Mellecker, 
Melody 
Case Manager, Short 
Term Follow Up 
North Dakota  Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
Holida, Myrl PA, Long Term Follow 
Up 
Lysosomal Storage 
Disorders 
Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
Johnson, Carol Program 
Administrator and 
Short Term Follow 
Up  
Iowa Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
Kremer, Courtney ARNP, Long Term 
Follow up 
SCID Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
Marcy, Jennifer Genetic Counselor, 
Short Term and Long 
Term Follow Up 
Counselor for all disorders; 
Short Term Follow Up for 
Cystic Fibrosis and 
Hemoglobinopathies along 
with Case Managers 
Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
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Miller, Judy ARNP, Long Term 
Follow Up 
Metabolic Disorders Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
Norris, Andrew MD Lead Medical 
Consultant 
Endocrine Disorders 
(Congenital Adrenal 
Hyperplasia; Congenital 
Hypothyroidism) 
Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
Phillips, Emily Case Manager, Short 
Term Follow Up 
South Dakota Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
Ramsey, Laura ARNP, Long Term 
Follow Up 
Cystic Fibrosis Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
Rumelhart, Stephen PA, Long Term Follow 
Up 
SCID Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
Serrano-Russi, Alvaro MD Medical 
Consultant 
Metabolic Disorders Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
Sharathkumar, Anjali MD Medical 
Consultant 
Hemoglobinopathies Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals 
and Clinics 
Iowa City, IA 
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Sheffield, Val Medical Director  Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals and 
Clinics 
Iowa City, IA 
Starner, Timothy MD Medical 
Consultant 
Cystic Fibrosis Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals and 
Clinics 
Iowa City, IA 
Stimson, Cheryl  Dietitian, Long Term 
Follow Up 
Metabolic Disorders Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals and 
Clinics 
Iowa City, IA 
Syrbu, Sergei MD Medical 
Consultant 
SCID, Flow Cytometry  Stead Family 
Department of 
Pediatrics, University 
of Iowa Hospitals and 
Clinics 
Iowa City, IA 
 
Although Short Term Follow Up Case Managers have a primary state assignment, they are cross 
trained to do follow up activities in all three states.  Case Managers cover all three states when 
they are on call on weekends and holidays.  In addition, the Case Mangers work on Iowa NBS 
projects, serve on Iowa NBS committees, and provide education for the Iowa NBS program.   
 
We had two new medical consultants join us during FY16.  Dr. Anjali Sharathkumar has replaced 
Dr. Natalie Kamberos as the medical consultant for hemoglobinopathies.  Dr. Timothy Starner 
has replaced Dr. Miles Weinberger as the medical consultant for cystic fibrosis.  Dr. Weinberger 
retired in FY 16 after serving as the medical consultant for cystic fibrosis since it was added to 
the NBS panel in Iowa.  Laura Ramsey, ARNP, replaces Elizabeth Dowd, ARNP, as the long term 
follow up nurse for cystic fibrosis.  Elizabeth retired in FY16.  Like Dr. Weinberger, Elizabeth 
served as the long term follow up nurse for cystic fibrosis since cystic fibrosis was added to the 
Iowa NBS panel.   
 
  
35 
 
Challenges 
 
The biggest challenge facing newborn screening nationally and in Iowa is the rapid addition to 
disorders on the RUSP.  In addition, the newest disorders added to the RUSP have both 
congenital and late onset presentations (anywhere from 3 months of life to 50 years of age).  
Finding the right balance between the public health perspective vs an individual perspective is a 
challenge.   
 
Another challenge is educating the stakeholders in newborn screening about newborn 
screening.  Many of the stakeholders, such as parents, don’t realize that they have a role to play 
in the newborn screening process.  A goal is to educate parents in the prenatal period rather 
than in the post-delivery setting or when an abnormality is found.  Primary care providers are 
also stakeholders in the newborn screening process.  As we know, PCPs are very busy people.  
What is the best way to educate PCPs throughout the state?  How do you educate their staff, 
who are often the person you talk to when calling with abnormal NBS results?  Midwife 
education is a particular challenge.  Midwives who are not affiliated with a birthing hospital are 
out there on their own, doing their own thing.  Many do not realize important issues related to 
NBS, particularly how important timeliness in NBS is.   
 
Contact Information 
 
Iowa Newborn Screening Follow Up  319-384-5097 
      iowanewbornscreening@uiowa.edu 
 
Carol Johnson     319-356-7248 
Iowa Newborn Screening Follow Up  carol-johnson@uiowa.edu 
  Coordinator 
 
 
  
36 
 
Appendix A 
 
Terms and Definitions Used in Newborn Screening and in this Report 
 
Against Medical Advice – Refers to a situation where medical advice is not followed by a 
patient/parent/guardian despite being educated about why it is important and the 
ramifications of not following medical advice 
 
Amino Acid Disorders – Babies born with one of these disorders cannot process certain amino 
acids in their body.  The amino acids, along with other toxic substances, build up in the body 
and cause serious effects on health, growth and learning.  Treatment may include a special diet 
for life, close monitoring and/or vitamin and amino acid supplements.  An example of an amino 
acid disorder is phenylketonuria (PKU).  Babies with PKU cannot process a substance called 
phenylalanine.  Left untreated, phenylalanine builds up in the bloodstream and causes brain 
damage, intellectual disability, depression, and other problems.   If PKU is detected early and 
the special diet is started by Day 10 of life, these problems can be greatly reduced or 
prevented.  PKU occurs in about 1 in every 12,000 births. 
 
Baby Matching – A term used in newborn screening where a birth certificate is “matched” with 
a newborn screening result or an official NBS refusal form to make sure that all babies born in 
the state have been screened.   
 
Beta Thalassemia – Beta thalassemia major usually causes severe anemia that can occur within 
months after birth. If left untreated, severe anemia can result in insufficient growth and 
development, as well as other common physical complications that can lead to a dramatically 
decreased life-expectancy. Fortunately, in developed countries beta thalassemia is usually 
identified by screening in the newborn period, before symptoms have developed. Children who 
are identified early can be started on ongoing blood transfusion therapy as needed. Although 
transfusion therapy prevents many of the complications of severe anemia, the body is unable 
to eliminate the excess iron contained in the transfused blood. Over time, the excess iron 
deposits in tissues and organs, resulting in damage and organ failure. Another medication must 
be administered to help the body eliminate the excess iron and prevent iron-over-load 
complications. Beta thalassemia intermedia describes the disease in individuals who have 
moderate anemia that only requires blood transfusions intermittently, if at all 
 
Biotinidase Deficiency – Babies with biotinidase deficiency cannot reuse the vitamin biotin.  
Biotin helps maintain the normal body functioning.  Without treatment, this disorder can lead 
to seizures, developmental delay, eczema and hearing loss.  Biotin has to be added to the diet 
for treatment of this disorder.  This disorder occurs in about 1 in every 60,000 births. 
 
Borderline - a term used for some newborn screening disorders where the results are not 
normal, but are not high enough to be considered presumptive positive.  A repeat screen on the 
baby is requested when the results are “borderline”.   
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Card – a card/form that contains circles with filter paper to deposit the blood from the baby’s 
heel on.  This card also contains demographic information regarding the baby, mother, and 
sample information.  Also called the “dried blood spot card”. 
 
Carrier – a person that has inherited a genetic trait or mutation but has no symptoms of the 
disease 
 
Confirmatory/Second Tier Testing – specific testing that is recommended and performed post 
newborn screening to determine if a baby has a specific disorder or not, e.g. a sweat test for 
cystic fibrosis. 
 
Confirmed – used to convey that the newborn screen and/or confirmatory testing determined 
that a baby had a disorder. 
 
Congenital – a condition or problem present at birth. 
 
Congenital Adrenal Hyperplasia – Babies born with this disorder have adrenal glands that 
cannot make enough of the hormone cortisol, and sometimes not enough of the hormone 
aldosterone.  Sometimes this disorder affects the development of the genitals.   You treat this 
disorder by taking medication that replaces the hormones that are deficient or eliminating the 
source of excess hormones.  Without treatment, severe cases of this disorder can cause death.  
This disorder occurs in about 1 in every 16,000 births. 
 
Congenital Hypothyroidism – Babies with this disorder are born with a thyroid gland that does 
not make enough thyroid hormone.  This can lead to poor growth and abnormal brain 
development.  If it is detected in time, a baby can be treated with medication.  This disorder 
occurs in about 1 in every 4,000 births. 
Courier – the contractual entity that travels to Iowa birthing facilities on a daily basis to pick up 
newborn screening cards and delivers them to the newborn screening laboratory. 
CRMS - When a person has a sweat test that gives an intermediate (borderline) result or a 
genetic test that shows only one CF gene, he or she is said to have CFTR-related metabolic 
syndrome (CRMS).   People with CRMS can be at a higher risk of having problems in the airways 
and sinuses; the intestines and pancreas; or the reproductive tract.  
Cystic Fibrosis – Cystic fibrosis (CF) is the most common inherited (genetic) disorder, affecting 
about 30,000 children and adults in the US.  A defective gene causes lung infections and 
digestive problems with malnutrition.  CF can be life-shortening⁵.  It’s important to diagnose CF 
early, so that CF health care providers can help parents learn ways to keep their child as healthy 
as possible and delay problems related to CF. Research shows that children who receive CF care 
early in life have better nutrition and are healthier than those who are diagnosed later. Good 
nutrition in CF is important for overall health and well-being. 
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Early Collection – the newborn screen was obtained prior to 24 hours of age.  The newborn 
screen is not valid if collected before 24 hours of age.  A repeat screen will be requested on the 
baby by program staff. 
 
False Negative – a term used when the newborn screen was negative, but a baby is found to 
have a disorder that we are screening for.   As stated above, the newborn screen is a screening 
test, not a diagnostic test.  Every attempt is made to reduce the number of false negatives, but 
it is understood that some cases will be missed.  It is an inherent part of newborn screening. 
 
False Positive – the newborn screen was positive for a particular disorder, but further testing 
was negative for the disorder. 
 
Fatty Acid Oxidation Disorders – Babies with fatty acid disorders are unable to breakdown 
stored fats for energy.  People who have this disorder cannot fast, and need prompt medical 
intervention when they have the stomach flu, fevers, etc.  One example of a fatty acid disorder 
is Medium Chain acyl-CoA Dehydrogenase Deficiency (MCAD).  Babies born with MCAD cannot 
break down fat into energy because an enzyme is missing or does not work correctly.  People 
with MCAD should not fast (go without food) for very long or they can experience low blood 
sugar, seizures, coma and even death.  MCAD occurs in about 1 in every 12,000 births. 
 
Galactosemia – Babies with this disorder cannot convert galactose, a sugar present in milk, into 
glucose, a sugar the body uses as an energy source.  Galactosemia can cause death in infancy, 
or blindness and intellectual disability.  A baby will this disorder is not able to drink milk and/or 
eat other dairy products. They have to drink special formula and follow a special diet for their 
lifetime.   This disorder occurs in about 1 in every 70,000 births. 
 
Hemoglobin E Disease - is an inherited blood disorder characterized by an abnormal form 
of hemoglobin, called hemoglobin E. People with this condition have red blood cells that are 
smaller than normal and have an irregular shape.  It is thought to be a benign condition. The 
mutation that causes hemoglobin E disease has the highest frequency among people of 
Southeast Asian heritage (Cambodian, Laotian, Vietnamese and Thai). However, it is also found 
in people of Chinese, Filipino, Asiatic Indian, and Turkish descent. 
 
Hemoglobin H Disease - Hemoglobin H disease is a relatively mild form of thalassemia that may 
go unrecognized. It is not generally considered a condition that will reduce one's life 
expectancy.  Transfusions are rarely needed in this disorder, except in a variant of this disorder 
called constant Spring.  Occasionally additional medication is required for treatment. 
 
 
Hemoglobinopathies – Hemoglobinopathies are inherited red blood cell disorders.  Hemoglobin 
is the protein in the blood that carries oxygen from the lungs to the body.  The most common 
hemoglobin disorder is sickle cell disease.  When sickle cell shaped cells block small blood 
vessels, less blood can reach that part of the body.  Sickle cell anemia occurs in about 1 in every 
375 African Americans. 
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Iowa Department of Public Health – state agency that administers and oversees newborn 
screening processes in Iowa. 
 
Long Term Follow Up - fundamentally, long-term follow-up comprises the assurance and 
provision of quality chronic disease management, condition-specific treatment, and age-
appropriate preventive care throughout the lifespan of individuals identified with a condition 
included in newborn screening. Integral to assuring appropriate long-term follow-up are activities 
related to improving care delivery, including engagement of affected individuals and their 
families as effective partners in care management, continuous quality improvement through the 
medical home, research into pathophysiology and treatment options, and active surveillance and 
evaluation of data related to care and outcomes. 
Lost to Follow Up – refers to situations where the baby cannot be located (moved with no 
forwarding address, guardian doesn’t respond to phone calls or certified letters) or when the 
guardian is contacted about further testing but doesn’t bring the baby in for further work up. 
 
Medical Consultant – A physician who makes medical recommendations for a specific disorder 
to the newborn screening program, state health department, and health care providers 
throughout the state.  They may also assist with development of protocols and provide 
education. 
 
Newborn Screening Laboratory - The newborn screening laboratory is part of the State Hygienic 
Laboratory at the University of Iowa (Ankeny campus).   This is the laboratory where the testing 
is performed. 
 
Organic Acidemia – Babies born with organic acid disorders have a chemical imbalance in their 
bodies which can be toxic.  Organic acids play an important role in the breakdown of fats, 
sugars and protein for the body’s use and storage.  Muscle wasting, seizures, developmental 
delays and even death can occur if untreated.  Treatment may include a special diet, monitoring 
and medications. 
 
Outcome – the final determination of a newborn screen, such as “confirmed, false positive, 
false negative, etc. 
 
Poor Quality – a term used to describe that the sample was not able to be tested.  A sample is 
called “poor quality” when the blood does not soak through the filter paper layers, when the 
sample is clotted, when too much blood is placed on the card, etc.  A repeat screen will be 
requested by program staff.   
 
Presumptive Positive – a term used by the laboratory and follow up personnel to identify a 
screen that was positive.  The term “presumptive” is used because until further testing is done, 
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the result is considered positive until the disorder is confirmed or determined to be a false 
positive. 
 
Primary Care Provider/Local Care Provider – also known as “PCP”.  The physician who is taking 
care of the baby, or is listed as the baby’s physician. 
 
Rejected Sample – similar to early collection and poor quality determinations. This term is 
usually used in association with a screen that was submitted after the 30 day cut off time 
frame.  It is also used when the screening card does not have enough information recorded on 
it to determine who the baby really was. 
 
Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC) - 
The committee advises the Secretary, U.S. Department of Health and Human Services on the 
most appropriate application of universal newborn screening tests, technologies, policies, 
guidelines and standards. Specifically, the committee provides to the Secretary, the following:  
Advice and recommendations concerning grants and projects authorized under the Heritable 
Disorders Program administered by the Health Resources and Services Administration; technical 
information to develop Heritable Disorders Program policies and priorities will enhance the 
ability of the state and local health agencies to provide screening, counseling and health care 
services for newborns and children who have or are at risk for heritable disorders; and 
recommendations, advice and information to enhance, expand or improve the ability of the 
Secretary to reduce mortality and morbidity from heritable disorders in newborns and children. 
The committee was chartered in February 2003. 
 
Short Term Follow Up - refers to the process of ensuring that all newborns are screened, that 
an appropriate caregiver is informed of results, that repeat testing on a new specimen or 
confirmatory testing has been completed, and that the infant has received a diagnosis and, if 
necessary, treatment. 
 
Sickle Cell Disease/Trait – Sickle cell anemia is caused by an abnormal type of hemoglobin called 
hemoglobin S. Hemoglobin is a protein inside red blood cells that carries oxygen. Hemoglobin S 
changes the shape of red blood cells. The red blood cells become shaped like crescents or 
sickles.The fragile, sickle-shaped cells deliver less oxygen to the body's tissues. They can also get 
stuck more easily in small blood vessels, as well as break into pieces that can interrupt healthy 
blood flow. These problems decrease the amount of oxygen flowing to body tissues even more. 
Sickle cell anemia is inherited from both parents. If you inherit the sickle cell gene from only 
one parent, you will have sickle cell trait. People with sickle cell trait do not have the symptoms 
of sickle cell anemia. Sickle cell disease is much more common in people of African and 
Mediterranean descent. It is also seen in people from South and Central America, the 
Caribbean, and the Middle East.  About 90,000-100,000 residents of the US have sickle cell 
disease.  One in every 500 blacks/African American’s have disease.  One in every 36,000 
Hispanics have sickle cell disease.  One in every 12 blacks/African American’s have sickle cell 
trait.   
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Tandem Mass Spectrometry (MS/MS) - Tandem mass spectrometry, also known as MS/MS or 
MS2, involves multiple steps of mass spectrometry selection, with some form of fragmentation 
occurring in between the stages.  In a tandem mass spectrometer, ions are formed in the ion 
source and separated by mass-to-charge ratio in the first stage of mass spectrometry (MS1). 
Ions of a particular mass-to-charge ratio (precursor ions) are selected and fragment ions 
(product ions) are created by collision-induced dissociation, ion-molecule reaction, 
photodissociation, or other process. The resulting ions are then separated and detected in a 
second stage of mass spectrometry (MS2).  This is the technology used for most metabolic 
disorders. 
 
Trait – a distinct, observable change in a person that might be inherited, such as sickle cell trait 
which can possibly be determined by newborn screening.  It is not true sickle cell disease. 
 
Unsatisfactory Specimen – a term used to state that there was not enough blood placed on the 
card to perform the newborn screen. 
 
 
